N/A N=44 Cirrhosis Medical Home
Cirrhosis, Liver
Primary: Enrollment Rate — 20; 20 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=155 A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis
Hepatic Cirrhosis · Liver Fibrosis · Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 48 — 28.2; 24.3; 28.2…
Phase 2 N=86 A Study of IDN-6556 in Subjects With Liver Cirrhosis
Liver Cirrhosis · Hepatic Cirrhosis
Primary: Change From Baseline at Month 3 in cCK18/M30 — 293.5; 257.5; 288.5; 285.0 U/L
N/A N=49 Probiotics for Liver Cirrhosis With Portal Hypertension
Liver Cirrhosis · Portal Hypertension
Primary: Admission Due to Complications Related to Portal Hypertension — 2; 3 participants — p=0.25
Phase 3 N=19 Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis
Liver Cirrhosis
Primary: Liver Stiffness by Transient Elastography (FibroScan) — 22.6; 23 kPa
Phase 3 N=95 Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
N/A N=232 Patient Buddy App for the Prevention of Avoidable Readmission in Cirrhosis
Cirrhosis
Primary: Avoidable Readmission — 23; 12 Number of Avoidable Readmissions
Phase 2 N=61 A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C
Hepatic Cirrhosis · Liver Fibrosis
Primary: The Number of Participants Who Achieve ≥ 1 Stage Improvement in Liver Fibrosis (METAVIR Score) as Determined by Liver Biopsy After 12 Weeks of Treatment — 3; 6; 2…
Phase 4 N=276 Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)
Chronic Liver Disease
Primary: PV Flow — 16.0; 15.5; 23.2; 27.1 ml/s
Phase 1 N=2 Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis
Hepatitis C · Liver Cirrhosis
Primary: AUC 0-∞ — 7240; 24700 h*ng/mL
Phase 3 N=414 BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis
Chronic Liver Disease
Primary: Number of Subjects With Likelihood of Cirrhosis Based on "Hepatic Impairment Score" (HIS) — 146 Participants — p=0.0924
N/A N=30 Improving Pain Management and Opioid Safety for Patients With Cirrhosis
Cirrhosis, Liver
Primary: Number of Participants Attending ≥80% of Intervention Sessions — 16; 5 Participants
Phase 1 N=9 Safety and Efficacy Study of Peripheral Blood Mononucleated Cells for Treatment of Liver Cirrhosis
Liver Cirrhosis
Primary: Number of Participants With Severe Adverse Events — 0; 0; 0 participants
N/A N=412 FibroTouch Non-invasive Evaluation of Liver Fibrosis and Cirrhosis
Liver Fibrosis · Cirrhosis · Chronic Hepatitis B
Primary: The Clinical Value Evaluation of FibroTouch for Non-invasive Diagnosis of Liver Fibrosis in Patients With Chronic Hepatitis B by Using Liver Pathology as the Gold…
Phase 2 N=25 Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver
Cirrhosis · Hepatocellular Carcinoma
Primary: Response (at Least a 50% Reduction in Liver Phospho-EGFR Staining) — 3; 3; 6 Participants
N/A N=51 Radiofrequency Ablation in Treating Patients With Liver Cancer and Cirrhosis
Liver Cancer
Primary: Proportion of Participants With Successful Control of Disease at 18 Months — .18 proportion of participants
N/A N=70 Velacur by Sonic Incytes for Portal Hypertension
Portal Hypertension · Chronic Advanced Liver Disease
Primary: Liver Stiffness Measurements for Participants With Compensated Advanced Chronic Liver Disease With and Without Esophageal Varices Upon Esophagogastroduodenoscopy (EGD)…
N/A N=1,061 Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder Messages
Fatty Liver, Nonalcoholic · Diabetes Mellitus, Type 2
Primary: Action on Suspected Advanced Liver Fibrosis — 55; 4 Participants
Phase 2 N=197 A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis
Liver Fibrosis · Nonalcoholic Fatty Liver Disease (NAFLD) · Nonalcoholic Steatohepatitis
Primary: The Percentage of Participants With Improvement in Fibrosis or Nonalcoholic Steatohepatitis (NASH) at Week 24 — 30.6; 24.0; 26.5; 14.3 Percentage of Participants — p=0.055
Phase 2 N=23 A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Liver Cirrhosis · Hepatic Cirrhosis · Portal Hypertension
Primary: Hepatic Venous Pressure Gradient (HVPG) — 15.2; 8.05; 20.62; 14.1 mmHg — p=0.257
Phase 3 N=60 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis
Chronic Hepatitis C Infection · Compensated Cirrhosis
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment — 100 percentage of participants
Phase 3 N=56 A Trial to Improve Quality of Life in People With Cirrhosis
Cirrhosis
Primary: Short Form-8 Health Survey (SF-8) at 28 Days — 8.1; 6.55; 70.9; 63.84 score on a scale — p=0.6
N/A N=106 Hepatic Effects of Gastric Bypass Surgery
Liver Diseases
Primary: Aspartate Transaminase (AST) Change — -6.32 U/L — p=0.03
Phase 4 N=10 Tolvaptan for Ascites in Cirrhotic Patients
Ascites · Cirrhosis
Primary: Number of Participants With Worsening Ascites (Increase in Number of Paracentesis Procedures to Remove 2 Liters of Ascites Fluid) — 0 participants
Phase 2 N=160 Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)
Compensated Cirrhosis · Nonalcoholic Steatohepatitis
Primary: Change From Baseline in Enhanced Liver Fibrosis Score at Week 48 — -0.071; 0.125; -0.213; 0.263 score on a scale
Phase 3 N=268 Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 83.3; 94.3; 87.8 percentage of participants…
N/A N=28 Chronic Liver Disease in Urea Cycle Disorders
Urea Cycle Disorder
Primary: Liver Stiffness as Measured by Shear Wave Elastography — 13; 14 Participants
N/A N=130 Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects
Cystic Fibrosis · Liver Fibrosis
Primary: Elastographic Value in kPa Measured by Fibroscan — 4.7 kPa
N/A N=232 Health IT Generated PROs to Improve Outcomes in Cirrhosis
Cirrhosis
Primary: Avoidable Readmissions — 12; 23 Number of avoidable readmissions
Phase 2 N=6 Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites
Cirrhosis · Ascites Hepatic
Primary: Clinical Safety of Terlipressin Infusion in Cirrhotic Patients With Refractory Ascites — 6; 4; 3; 0 Participants